Holen Sie sich die Stockscreener-App
2.05
0.00%
0.00
Handel nachbörslich:
2.06
0.01
+0.49%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.07
24-Stunden-Volumen:
3.51M
Relative Volume:
0.21
Marktkapitalisierung:
$256.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.46M
KGV:
-1.25
EPS:
-1.64
Netto-Cashflow:
$-99.89M
1W Leistung:
-8.69%
1M Leistung:
+753.10%
6M Leistung:
+56.49%
1J Leistung:
+121.62%
1-Tages-Spanne:
$1.97
$2.12
1-Wochen-Bereich:
$1.92
$2.65
52-Wochen-Spanne:
$0.1311
$3.29
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Vergleichen Sie VOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
2.05 | 280.53M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
What analysts say about Vor Biopharma Inc. stockFree Bull & Bear Market Updates - jammulinksnews.com
What drives Vor Biopharma Inc. stock priceFree Stock Market Beginners Guide - jammulinksnews.com
Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop - Yahoo Finance
Vor Biopharma Inc. Stock Analysis and ForecastUnprecedented profits - jammulinksnews.com
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target - MSN
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Is Vor Biopharma Inc. a good long term investmentExplosive portfolio gains - jammulinksnews.com
Vor Biopharma's Strategic Turnaround and the Case for Immediate Investment - AInvest
Vor Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio Awards Massive 5.3M Share Package to New Development Chief: Full Grant Details Revealed - Stock Titan
Vor Biopharma shares rise 2.52% premarket after appointing Qing Zuraw as Chief Development Officer. - AInvest
Why Vor Biopharma Inc. stock is on top investor watchlistsFree Real-Time Market Predictions - Newser
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Yahoo Finance
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
Vor Biopharma Inc. shares rise 2.00% premarket after Bonesupport CEO predicts strong growth. - AInvest
How Vor Biopharma Inc. stock performs during market volatilitySafe Entry High Exit Alerts - Newser
What makes Vor Biopharma Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - newser.com
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
VOR’s 2025 Market Dance: Up 174.66% – Time to Invest? - investchronicle.com
Vor Biopharma Explodes 22% – What’s Fueling the Surge? - AInvest
Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer - MarketScreener
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer - The Manila Times
Vor Bio Strengthens Leadership: Top Biotech Executive Who Raised $6B Joins as New CFO/CBO - Stock Titan
Vor Biopharma shares rise 5.83% intraday after $41B telitacicept licensing deal and HC Wainwright upgrade. - AInvest
Vor Biopharma Sees Unusually High Options Volume (NYSE:VOR) - Defense World
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
VOR’s Unexpected Surge: What’s Driving the Spike? - timothysykes.com
VOR Biopharma Inc. Faces Uncertain Future Amid Recent Developments - StocksToTrade
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):